Tesamorelin before and after: what the trials measured

The short answer: in controlled trials, tesamorelin's "before and after" was a smaller waistline on a CT scan, not a different body in a mirror. Adults with HIV and excess abdominal fat who took tesamorelin daily for 26 weeks lost about 15% more visceral fat than people on placebo, their weight barely moved, and the fat came back when they stopped. [5] Those numbers are the honest baseline for any tesamorelin results claim, including the photos that circulate online.

This post covers what the trials measured, when changes showed up, what happened after stopping, and why photos are not trial data. It does not give dosing advice. The FDA label dose lives on the tesamorelin page, and this post links there rather than repeating it.

What did tesamorelin before and after results look like in the trials?

Tesamorelin is FDA approved as Egrifta for one use: reducing excess abdominal fat in adults with HIV who have lipodystrophy. [1] Two multicenter, double-blind, placebo-controlled phase 3 trials supported that approval, and both measured visceral adipose tissue (the fat packed around the abdominal organs) with a CT scan at the level of the lower spine. [1]

• First trial, 412 patients. After 26 weeks, visceral fat fell 15.2% with tesamorelin and rose 5.0% with placebo. Triglycerides dropped by 50 mg/dL versus a rise of 9 mg/dL. [2]
• Second trial, 404 patients. Visceral fat fell 10.9% with tesamorelin versus 0.6% with placebo at 6 months, and trunk fat, waist circumference, and waist to hip ratio improved, with no change in fat on the limbs or under the skin of the abdomen. [4]
• Pooled, 806 patients. Visceral fat changed by minus 24 versus plus 2 square centimeters, a treatment effect of minus 15.4%. Abdominal subcutaneous fat did not change significantly. [5]

People also reported feeling better about how their belly looked. Patient ratings of belly appearance distress and physician ratings of belly profile both improved compared with placebo. [5] That is the closest thing the trials have to a before and after photo, and it was measured with a validated scale rather than a camera.

Two smaller trials asked a related question. In 50 patients at one hospital, 6 months of tesamorelin reduced visceral fat and produced a modest drop in liver fat. [6] In a 12 month trial of 61 people with HIV and fatty liver, liver fat fell by an absolute 4.1 percentage points and more patients cleared their steatosis than on placebo. [7] The fatty liver disease page grades that evidence alongside other options.

What tesamorelin results do not include

Three things are missing from the trial results that people often expect.

1. Weight loss. Mean body weight changed by half a kilogram or less in either direction in both trials at 26 weeks, no different from placebo. The label states plainly that the drug is not indicated for weight loss management because it has a weight neutral effect. [1]
2. Loss of fat under the skin. The pinchable fat on the belly did not change significantly. [5] Visceral fat sits deeper, which is why a measurable CT change can be hard to see from the outside.
3. A large waist change. Waist circumference fell by about 1 to 2 centimeters more than placebo at 26 weeks. [1] Real, but small.

What did change beyond fat: lean body mass rose by about 1.2 to 1.3 kilograms in the tesamorelin groups. We cover what that number does and does not mean in does tesamorelin build muscle.

How long does tesamorelin take to work?

The honest answer is that the trials were not designed to show the first week a change appears. They scanned visceral fat at the start, at 26 weeks, and at 52 weeks. [1] So the evidence supports "by 26 weeks," not "in two weeks."

The blood marker moved sooner. Tesamorelin raises growth hormone and therefore IGF-1, and the label reports that many patients had IGF-1 levels more than 2 standard deviations above normal, with this effect seen as early as 13 weeks. [1] In the pooled trials, IGF-1 rose by an average of 108 ng/mL at 26 weeks. [5] A rising lab value is a sign the drug is active, not proof that fat is coming off.

The label also tells prescribers to weigh whether to continue in patients who have not had a reduction in visceral fat. [1] In other words, not everyone responds, and a trial of therapy is expected to show a measurable effect.

Does tesamorelin keep working, and what happens when you stop?

The 52 week data answer both halves of this question, because the trials re-randomized patients at week 26.

• Staying on it. Patients who continued tesamorelin for a full year kept their reduction. In the pooled analysis, visceral fat at 52 weeks was down 17.5% from the original baseline, with waist circumference down 3.4 centimeters and triglycerides down 48 mg/dL. [5]
• Stopping. Patients switched to placebo after 26 weeks regained visceral fat. In the label's extension data, visceral fat rose 22% and 16% in the two switched groups over the next 26 weeks, while trunk fat rose by about 1.1 to 1.4 kilograms and lean body mass fell by about 1.7 to 1.8 kilograms. [1]

The authors of the first trial's extension put it directly: the effect on visceral fat is sustained during treatment but does not last beyond it. [3] The second trial reported the same pattern, with early improvements rapidly lost after switching to placebo. [4] Any before and after story that stops the clock at the end of a course is leaving out the part where the fat returns.

Tesamorelin before and after in men

Searches for tesamorelin results in men make sense, because the trial population was mostly men. In the two phase 3 trials, 86% and 84% of participants were male, with a mean age of 48 and a mean BMI of 29. [1] Every participant had HIV, was on stable antiretroviral therapy, and had a large waist and high waist to hip ratio at entry. People with type 1 diabetes, or diabetes treated with insulin or oral drugs, were excluded. [1]

So the trial results describe men with HIV and central fat gain on antiretroviral therapy. They do not describe a lean 30 year old trying to sharpen abdominal definition, and no trial has tested that.

Does tesamorelin work for people without HIV?

One randomized trial speaks to this. Sixty adults with abdominal obesity and reduced growth hormone secretion, without HIV, took tesamorelin or placebo for 12 months. Visceral fat changed by minus 16 versus plus 19 square centimeters, triglycerides and C-reactive protein improved, and fasting glucose and HbA1c did not change. [8] Subcutaneous abdominal fat, again, did not change significantly. [8]

That is encouraging but small, and it enrolled a specific group: people with measured low growth hormone output. It is not an approval, and it does not show results in people with normal growth hormone. Our fat loss and body composition page ranks tesamorelin against the GLP-1 drugs, which have far larger trials for weight. For tesamorelin's head to head with a newer metabolic drug, see tesamorelin vs retatrutide.

Why before and after photos are not trial data

Photos posted as tesamorelin before and after pictures cannot tell you what the drug did, for reasons that apply to every peptide:

• No control group. The trials compared against placebo because waists change with diet, training, and time. In the first phase 3 trial, the placebo group's visceral fat rose 5% over 26 weeks. [2] A photo has no placebo arm.
• Visceral fat is not visible. The drug's main effect is on fat around the organs, measured by CT, while subcutaneous belly fat did not change. [5] Visible change in a photo usually reflects something else.
• Unknown product. Compounded or research-labeled products are not the FDA approved formulation and have no lawful basis for human use. A photo cannot confirm what was injected.
• Stacking and lifestyle. Posts often combine tesamorelin with other compounds, diet changes, and training, so no single cause can be separated. No trial has tested tesamorelin combined with ipamorelin; see the tesamorelin and ipamorelin blend page.
• Selection. People share their best results. The trials report everyone, including non-responders.

Our broader guide to peptide before and after claims applies the same test to other products.

Safety context for the results

The results came with trade-offs listed on the label. Injection site reactions occurred in 25% of tesamorelin patients versus 14% on placebo in the first 26 weeks, and the label warns about fluid retention, joint pain, glucose intolerance, and persistently high IGF-1, with monitoring recommended. [1] It is contraindicated in active malignancy, pregnancy, and disorders of the pituitary axis. [1] Tesamorelin is also prohibited at all times for tested athletes. [9]

How to get tesamorelin legally

Tesamorelin is the one catalog peptide with a lawful prescription path today. Egrifta WR is prescribed for the approved HIV indication, and a clinician may prescribe it off-label. Tesamorelin is a biologic: Egrifta moved to a biologics license (BLA 022505) on March 23, 2020, and FDA states that biological products are not eligible for the 503A or 503B compounding exemptions, so compounded tesamorelin has no lawful basis. [11] [12] Egrifta WR is the only lawful product.

Our tesamorelin prescription guide covers who qualifies and what a visit involves, the tesamorelin cost page lists dated prices by channel, and the tesamorelin regulatory tracker records status changes. For the approved indication itself, start with the HIV lipodystrophy page. For how tesamorelin compares with the older GHRH fragment, see sermorelin vs tesamorelin and our three-way tesamorelin vs sermorelin vs ipamorelin table. State rules for telehealth prescribing are on the legality hub, and the general route to a lawful prescription is in how to get peptides prescribed. If a clinic calls this peptide therapy, our explainer on what peptide therapy means sorts approved drugs from compounded and research-labeled products.